Alar Pharmaceuticals

6785.TWO

4.37 USD

-0.11

-2.46%

Overview

Last close

4.37 usd

Market cap

292.04M usd

52 week high

9.84 usd

52 week low

3.40 usd

Target price

9.25 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

3324.228

Price/Book Value

3.8498

Enterprise Value

222.05M usd

EV/Revenue

2527.781

EV/EBITDA

21.9707

Key financials

Revenue TTM

87843.01 usd

Gross Profit TTM

68283.34 usd

EBITDA TTM

-5.28M usd

Earnings per Share

-0.04 usd

Dividend

N/A usd

Total assets

79.25M usd

Net debt

N/A usd

About

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson's disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.